Skip to main content
SpringerLink
Log in

Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000–2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000–2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000–2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Krouwer HG, Van Duinen SG, Kamphorst W, Van Der Valk P, Algra A (1997) Oligoastrocytomas: a clinicopathological study of 52 cases. J Neurooncol 33:223–238

    Article  CAS  PubMed  Google Scholar 

  2. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro oncology 14:v1–v49

    Article  PubMed Central  PubMed  Google Scholar 

  3. NCCN guidelines version 1.2014. http://www.NCCN.org/. Accessed 16 April 2014

  4. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  CAS  PubMed  Google Scholar 

  5. DeAngelis LM (2009) Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol 27:5861–5862

    Article  PubMed  Google Scholar 

  6. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann neurol 23:360–364

    Article  CAS  PubMed  Google Scholar 

  7. Kim L, Hochberg FH, Thornton AF, Harsh GR IV, Patel H, Finkelstein D, Louis DN (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602–607

    Article  CAS  PubMed  Google Scholar 

  8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed Central  PubMed  Google Scholar 

  9. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333–343. doi:10.3171/jns.1978.49.3.0333

    Article  CAS  PubMed  Google Scholar 

  10. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021

    CAS  PubMed  Google Scholar 

  11. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145

    Article  PubMed  Google Scholar 

  12. Bouffet E, Jouvet A, Thiesse P, Sindou M (1998) Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment. Br J Neurosurg 12:217–222. doi:10.1080/02688699845023

    Article  CAS  PubMed  Google Scholar 

  13. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-Y, Bernsen HJ, Frenay M, Tijssen CC, Grisold W (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350

    Article  PubMed  Google Scholar 

  14. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    Article  CAS  PubMed  Google Scholar 

  16. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276–1284. doi:10.1002/cncr.11187

    Article  PubMed  Google Scholar 

  17. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS (2012) Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro oncology 14:761–767

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro oncology 13:649–659

    Article  PubMed Central  PubMed  Google Scholar 

  19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  20. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J (1999) Combined treatment modality for anaplastic oligodendroglioma: a phase II study. J Neurooncol 43:179–185. doi:10.1023/A:1006206800947

    Article  CAS  PubMed  Google Scholar 

  21. Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in the CT/MR-Era. Acta Neurochir (Wien) 143:1195–1203. doi:10.1007/s007010100014

    Article  CAS  Google Scholar 

  22. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37:399–403. doi:10.1016/S0360-3016(96)00452-X

    Article  CAS  PubMed  Google Scholar 

  23. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    Article  CAS  PubMed  Google Scholar 

  24. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    Article  PubMed  Google Scholar 

  25. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363–4367

    CAS  PubMed  Google Scholar 

  26. Chinot O-L, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin P-M, Grisoli F (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19:2449–2455

    CAS  PubMed  Google Scholar 

  27. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153–157

    Article  CAS  PubMed  Google Scholar 

  28. Van den Bent M, Taphoorn M, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros J, van der Rijt C, Vecht CJ (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525–2528

    Article  PubMed  Google Scholar 

  29. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746–4753

    Article  CAS  PubMed  Google Scholar 

  30. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 11:167–175. doi:10.1215/15228517-2008-073

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J clin oncol 17:2762–2771

    CAS  PubMed  Google Scholar 

  32. Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M (2006) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 8:253–260. doi:10.1215/15228517-2006-005

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715

    Article  CAS  PubMed  Google Scholar 

  34. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens E, Strauven T, D’Hondt L, Sartenaer D (2009) MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45:146–153

    Article  CAS  PubMed  Google Scholar 

  35. Anderson MD, Gilbert MR (2014) Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). J Natl Compr Canc Netw 12:665–672

    PubMed  Google Scholar 

  36. Health Insurance Review & Assessment Service, Korea. http://www.hira.or.kr/. Accessed 16 April 2014

Download references

Acknowledgments

This work is the collaborative effort of The Brain Tumor Committee of the Korean Radiation Oncology Group. This work was supported by the Cancer Control Program from the Korean Ministry of Health & Welfare (#0820010 to Kim IA).

Conflict of interest

All authors report that they have no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea

    Tosol Yu, Il Han Kim & In Ah Kim

  2. Department of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea

    Hyun-Cheol Kang

  3. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Do Hoon Lim

  4. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea

    Woong-Ki Chung

  5. Department of Radiation Oncology, Yonsei Cancer Center, College of Medicine, Yonsei University, Seoul, Korea

    Chang-Ok Suh

  6. Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Korea

    Byung Ock Choi

  7. Proton Therapy Center, Research Institute Hospital, National Cancer Center, Goyang, Korea

    Kwan Ho Cho

  8. Department of Radiation Oncology, Gangnam Severance Cancer Hospital, Seoul, Korea

    Jae Ho Cho

  9. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea

    Jin Hee Kim

  10. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

    Chul-Kee Park

  11. Department of Neurosurgery, College of Medicine, The Catholic University of Korea, Seoul, Korea

    Yong-Kil Hong

  12. Department of Radiation Oncology, Seoul National University Bundang Hospital, 166 Gumiro Seongnamsi Kyeonggido, Seoul, 463-707, Korea

    In Ah Kim

Authors
  1. Tosol Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyun-Cheol Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Do Hoon Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Il Han Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Woong-Ki Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chang-Ok Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Byung Ock Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kwan Ho Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jae Ho Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jin Hee Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chul-Kee Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yong-Kil Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. In Ah Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Ah Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, T., Kang, HC., Lim, D.H. et al. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. J Neurooncol 121, 531–539 (2015). https://doi.org/10.1007/s11060-014-1660-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1660-6

Keywords

Search

Navigation